Literature DB >> 9467474

Comparison of the Danish Prostatic Symptom Score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. ALFECH Study Group.

B J Hansen, S Mortensen, H J Mensink, H Flyger, M Riehmann, N Hendolin, J Nordling, T Hald.   

Abstract

OBJECTIVE: To compare the Danish Prostatic Symptom Score (DAN-PSS) with the International Prostatic Symptom Score (IPSS). Madsen-Iversen and Boyarsky symptom indexes in a clinical setting, and to evaluate the potential significance of any differences in information obtained from these questionnaires. PATIENTS AND METHODS: The study comprised two substudies: in the first, 205 patients with lower urinary tract symptoms (LUTS) suggestive of bladder outlet obstruction (BOO), a Madsen-Iversen score > 6 and a maximum flow rate of < 10 mL/s were randomized to receive either placebo or alfuzosin in a double-blind study of 16 weeks. The symptoms were assessed using the Madsen-Iversen, DAN-PSS and the IPSS questionnaires. In the second, 138 patients with LUTS suggestive of BOO were selected for treatment with transurethral microwave thermotherapy (TUMT, 52 degrees C for 60 min, microwave energy 200 kJ) and their symptoms assessed using the Boyarsky and the DAN-PSS questionnaires. Patients were then followed for one year. Rank correlation coefficients and regression lines were calculated using Spearman's non-parametric test. The relative changes, i.e. responsiveness, calculated for the DAN-PSS, IPSS and Boyarsky indexes were compared pairwise using the Wilcoxon-Pratt test.
RESULTS: The DAN-PSS, IPSS and Madsen-Iversen indexes were correlated on a pairwise basis. The DAN-PSS and IPSS indexes have significant construct validity in terms of correlation with the Madsen-Iversen system (Spearman's correlation coefficient, rs = 0.51 and rs = 0.45, respectively). The DAN-PSS and the IPSS indexes were correlated (rs = 0.61). The DAN-PSS was more sensitive than the IPSS to changes after pharmacological treatment, with scores decreasing 70% and 29% (P < 0.05), respectively, after treatment with an alpha-blocker for 4 months, and 50% and 29% (P < 0.05), respectively, after 4 months on placebo treatment. Finally, the responsiveness of the Boyarsky and DAN-PSS indexes to TUMT showed that the DAN-PSS system was significantly more responsive than the Boyarsky index, with scores decreasing 57% and 15% (P < 0.05), respectively, after one year.
CONCLUSIONS: The DAN-PSS index is more sensitive than the IPSS, Madsen-Iversen and Boyarsky symptom indexes, incorporates important outcome events, includes a patient-weighting of each symptom, thereby reflecting better the patients' global assessment of outcome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467474     DOI: 10.1046/j.1464-410x.1998.00524.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  8 in total

Review 1.  Lower urinary tract disease: what are we trying to treat and in whom?

Authors:  Jeremy P W Heaton
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

2.  Performance of the American Urological Association Symptom Index with and without an additional urge incontinence item.

Authors:  Michael J Barry; Andrew L Avins; Sreelatha Meleth
Journal:  Urology       Date:  2011-07-08       Impact factor: 2.649

3.  Prostatic profile, premature ejaculation, erectile function and andropause in an at-risk Mexican population.

Authors:  J Jaspersen-Gastelum; J A Rodríguez; F J Espinosa de los Monteros; L Beas-Sandoval; José Guzmán-Esquivel; D D Calvo; T Gutiérrez
Journal:  Int Urol Nephrol       Date:  2008-07-15       Impact factor: 2.370

Review 4.  Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations.

Authors:  Anne Pavy-Le Traon; Nikki Cotterill; Gerard Amarenco; Susanne Duerr; Horacio Kaufmann; Heinz Lahrmann; François Tison; Gregor K Wenning; Christopher G Goetz; Werner Poewe; Cristina Sampaio; Anette Schrag; Olivier Rascol; Pablo Martinez-Martin; Glenn T Stebbins
Journal:  Mov Disord Clin Pract       Date:  2018-10-25

Review 5.  Symptom scores: mumbo jumbo or meaningful measures?

Authors:  A Christopher Stage; John C Hairston
Journal:  Curr Urol Rep       Date:  2005-07       Impact factor: 2.862

Review 6.  Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis.

Authors:  Juan Va Franco; Jae Hung Jung; Mari Imamura; Michael Borofsky; Muhammad Imran Omar; Camila Micaela Escobar Liquitay; Shamar Young; Jafar Golzarian; Areti Angeliki Veroniki; Luis Garegnani; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2021-07-15

Review 7.  Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function.

Authors:  A Hoznek; C C Abbou
Journal:  Curr Urol Rep       Date:  2001-08       Impact factor: 2.862

8.  Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Juan Va Franco; Luis Garegnani; Camila Micaela Escobar Liquitay; Michael Borofsky; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2021-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.